within Pharmacolibrary.Drugs.ATC.J;

model J05AE16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 13.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 375 / 1000000,
    adminCount     = 1,
    Vd             = 0.128,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016333333333333334,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Ensitrelvir is an oral antiviral drug that acts as a SARS-CoV-2 3CL protease inhibitor. It is approved in Japan for the treatment of COVID-19 in adult and pediatric patients. The drug is used to shorten the duration of symptoms and reduce viral replication in patients infected with COVID-19.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult Japanese male participants. Single oral dose, fasted state.</p><h4>References</h4><ol><li><p>Shimizu, R, et al., &amp; Kubota, R (2022). Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults. <i>Antimicrobial agents and chemotherapy</i> 66(10) e0063222–None. DOI:<a href=&quot;https://doi.org/10.1128/aac.00632-22&quot;>10.1128/aac.00632-22</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36094202/&quot;>https://pubmed.ncbi.nlm.nih.gov/36094202</a></p></li><li><p>Shimizu, R, et al., &amp; Kubota, R (2023). A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations. <i>Clinical drug investigation</i> 43(10) 785–797. DOI:<a href=&quot;https://doi.org/10.1007/s40261-023-01309-z&quot;>10.1007/s40261-023-01309-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37798608/&quot;>https://pubmed.ncbi.nlm.nih.gov/37798608</a></p></li><li><p>Ishibashi, T, et al., &amp; Kubota, R (2024). Population Pharmacokinetics of Ensitrelvir in Healthy Participants and Participants with SARS-CoV-2 Infection in the SCORPIO-SR Study. <i>Clinical pharmacokinetics</i> 63(12) 1723–1734. DOI:<a href=&quot;https://doi.org/10.1007/s40262-024-01446-4&quot;>10.1007/s40262-024-01446-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39565561/&quot;>https://pubmed.ncbi.nlm.nih.gov/39565561</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AE16;
